Aflibercept Biosimilars Market

1 Aflibercept Biosimilars Market Overview
    1.1 Product Overview and Scope of Aflibercept Biosimilars
    1.2 Aflibercept Biosimilars Segment by Type
        1.2.1 Global Aflibercept Biosimilars Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Intravitreal Injection
        1.2.3 Intravenous Injection
    1.3 Aflibercept Biosimilars Segment by Application
        1.3.1 Global Aflibercept Biosimilars Sales Comparison by Application: (2022-2028)
        1.3.2 Wet Macular Degeneration
        1.3.3 Metastatic Colorectal Cancer
    1.4 Global Aflibercept Biosimilars Market Size Estimates and Forecasts
        1.4.1 Global Aflibercept Biosimilars Revenue 2017-2028
        1.4.2 Global Aflibercept Biosimilars Sales 2017-2028
        1.4.3 Aflibercept Biosimilars Market Size by Region: 2017 Versus 2021 Versus 2028
2 Aflibercept Biosimilars Market Competition by Manufacturers
    2.1 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Aflibercept Biosimilars Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Aflibercept Biosimilars Manufacturing Sites, Area Served, Product Type
    2.5 Aflibercept Biosimilars Market Competitive Situation and Trends
        2.5.1 Aflibercept Biosimilars Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Aflibercept Biosimilars Players Market Share by Revenue
        2.5.3 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Aflibercept Biosimilars Retrospective Market Scenario by Region
    3.1 Global Aflibercept Biosimilars Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Aflibercept Biosimilars Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Aflibercept Biosimilars Market Facts & Figures by Country
        3.3.1 North America Aflibercept Biosimilars Sales by Country
        3.3.2 North America Aflibercept Biosimilars Revenue by Country
        3.3.3 United States
        3.3.4 Canada
    3.4 Europe Aflibercept Biosimilars Market Facts & Figures by Country
        3.4.1 Europe Aflibercept Biosimilars Sales by Country
        3.4.2 Europe Aflibercept Biosimilars Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Aflibercept Biosimilars Market Facts & Figures by Region
        3.5.1 Asia Pacific Aflibercept Biosimilars Sales by Region
        3.5.2 Asia Pacific Aflibercept Biosimilars Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 China Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
    3.6 Latin America Aflibercept Biosimilars Market Facts & Figures by Country
        3.6.1 Latin America Aflibercept Biosimilars Sales by Country
        3.6.2 Latin America Aflibercept Biosimilars Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Aflibercept Biosimilars Market Facts & Figures by Country
        3.7.1 Middle East and Africa Aflibercept Biosimilars Sales by Country
        3.7.2 Middle East and Africa Aflibercept Biosimilars Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Aflibercept Biosimilars Historic Market Analysis by Type
    4.1 Global Aflibercept Biosimilars Sales Market Share by Type (2017-2022)
    4.2 Global Aflibercept Biosimilars Revenue Market Share by Type (2017-2022)
    4.3 Global Aflibercept Biosimilars Price by Type (2017-2022)
5 Global Aflibercept Biosimilars Historic Market Analysis by Application
    5.1 Global Aflibercept Biosimilars Sales Market Share by Application (2017-2022)
    5.2 Global Aflibercept Biosimilars Revenue Market Share by Application (2017-2022)
    5.3 Global Aflibercept Biosimilars Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Regeneron
        6.1.1 Regeneron Corporation Information
        6.1.2 Regeneron Description and Business Overview
        6.1.3 Regeneron Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Regeneron Aflibercept Biosimilars Product Portfolio
        6.1.5 Regeneron Recent Developments/Updates
    6.2 Sanofi
        6.2.1 Sanofi Corporation Information
        6.2.2 Sanofi Description and Business Overview
        6.2.3 Sanofi Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Sanofi Aflibercept Biosimilars Product Portfolio
        6.2.5 Sanofi Recent Developments/Updates
    6.3 Novartis
        6.3.1 Novartis Corporation Information
        6.3.2 Novartis Description and Business Overview
        6.3.3 Novartis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Novartis Aflibercept Biosimilars Product Portfolio
        6.3.5 Novartis Recent Developments/Updates
    6.4 Genentech
        6.4.1 Genentech Corporation Information
        6.4.2 Genentech Description and Business Overview
        6.4.3 Genentech Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Genentech Aflibercept Biosimilars Product Portfolio
        6.4.5 Genentech Recent Developments/Updates
    6.5 Roche
        6.5.1 Roche Corporation Information
        6.5.2 Roche Description and Business Overview
        6.5.3 Roche Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Roche Aflibercept Biosimilars Product Portfolio
        6.5.5 Roche Recent Developments/Updates
    6.6 Pfizer
        6.6.1 Pfizer Corporation Information
        6.6.2 Pfizer Description and Business Overview
        6.6.3 Pfizer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Pfizer Aflibercept Biosimilars Product Portfolio
        6.6.5 Pfizer Recent Developments/Updates
    6.7 Sartorius
        6.6.1 Sartorius Corporation Information
        6.6.2 Sartorius Description and Business Overview
        6.6.3 Sartorius Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Sartorius Aflibercept Biosimilars Product Portfolio
        6.7.5 Sartorius Recent Developments/Updates
    6.8 Eli Lilly
        6.8.1 Eli Lilly Corporation Information
        6.8.2 Eli Lilly Description and Business Overview
        6.8.3 Eli Lilly Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Eli Lilly Aflibercept Biosimilars Product Portfolio
        6.8.5 Eli Lilly Recent Developments/Updates
    6.9 Bayer
        6.9.1 Bayer Corporation Information
        6.9.2 Bayer Description and Business Overview
        6.9.3 Bayer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Bayer Aflibercept Biosimilars Product Portfolio
        6.9.5 Bayer Recent Developments/Updates
    6.10 Amgen
        6.10.1 Amgen Corporation Information
        6.10.2 Amgen Description and Business Overview
        6.10.3 Amgen Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Amgen Aflibercept Biosimilars Product Portfolio
        6.10.5 Amgen Recent Developments/Updates
    6.11 PlantForm
        6.11.1 PlantForm Corporation Information
        6.11.2 PlantForm Aflibercept Biosimilars Description and Business Overview
        6.11.3 PlantForm Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 PlantForm Aflibercept Biosimilars Product Portfolio
        6.11.5 PlantForm Recent Developments/Updates
    6.12 PharmaPraxis
        6.12.1 PharmaPraxis Corporation Information
        6.12.2 PharmaPraxis Aflibercept Biosimilars Description and Business Overview
        6.12.3 PharmaPraxis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 PharmaPraxis Aflibercept Biosimilars Product Portfolio
        6.12.5 PharmaPraxis Recent Developments/Updates
    6.13 Samsung Bioepis
        6.13.1 Samsung Bioepis Corporation Information
        6.13.2 Samsung Bioepis Aflibercept Biosimilars Description and Business Overview
        6.13.3 Samsung Bioepis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 Samsung Bioepis Aflibercept Biosimilars Product Portfolio
        6.13.5 Samsung Bioepis Recent Developments/Updates
    6.14 Centus
        6.14.1 Centus Corporation Information
        6.14.2 Centus Aflibercept Biosimilars Description and Business Overview
        6.14.3 Centus Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.14.4 Centus Aflibercept Biosimilars Product Portfolio
        6.14.5 Centus Recent Developments/Updates
    6.15 Cadila Pharmaceuticals
        6.15.1 Cadila Pharmaceuticals Corporation Information
        6.15.2 Cadila Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
        6.15.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.15.4 Cadila Pharmaceuticals Aflibercept Biosimilars Product Portfolio
        6.15.5 Cadila Pharmaceuticals Recent Developments/Updates
    6.16 Dr Reddy's
        6.16.1 Dr Reddy's Corporation Information
        6.16.2 Dr Reddy's Aflibercept Biosimilars Description and Business Overview
        6.16.3 Dr Reddy's Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.16.4 Dr Reddy's Aflibercept Biosimilars Product Portfolio
        6.16.5 Dr Reddy's Recent Developments/Updates
    6.17 Aurobindo Pharma
        6.17.1 Aurobindo Pharma Corporation Information
        6.17.2 Aurobindo Pharma Aflibercept Biosimilars Description and Business Overview
        6.17.3 Aurobindo Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.17.4 Aurobindo Pharma Aflibercept Biosimilars Product Portfolio
        6.17.5 Aurobindo Pharma Recent Developments/Updates
    6.18 Biocad
        6.18.1 Biocad Corporation Information
        6.18.2 Biocad Aflibercept Biosimilars Description and Business Overview
        6.18.3 Biocad Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.18.4 Biocad Aflibercept Biosimilars Product Portfolio
        6.18.5 Biocad Recent Developments/Updates
    6.19 MAbxience
        6.19.1 MAbxience Corporation Information
        6.19.2 MAbxience Aflibercept Biosimilars Description and Business Overview
        6.19.3 MAbxience Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.19.4 MAbxience Aflibercept Biosimilars Product Portfolio
        6.19.5 MAbxience Recent Developments/Updates
    6.20 Hetero
        6.20.1 Hetero Corporation Information
        6.20.2 Hetero Aflibercept Biosimilars Description and Business Overview
        6.20.3 Hetero Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.20.4 Hetero Aflibercept Biosimilars Product Portfolio
        6.20.5 Hetero Recent Developments/Updates
    6.21 Biocon
        6.21.1 Biocon Corporation Information
        6.21.2 Biocon Aflibercept Biosimilars Description and Business Overview
        6.21.3 Biocon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.21.4 Biocon Aflibercept Biosimilars Product Portfolio
        6.21.5 Biocon Recent Developments/Updates
    6.22 Kirin Biologics
        6.22.1 Kirin Biologics Corporation Information
        6.22.2 Kirin Biologics Aflibercept Biosimilars Description and Business Overview
        6.22.3 Kirin Biologics Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.22.4 Kirin Biologics Aflibercept Biosimilars Product Portfolio
        6.22.5 Kirin Biologics Recent Developments/Updates
    6.23 Mylan
        6.23.1 Mylan Corporation Information
        6.23.2 Mylan Aflibercept Biosimilars Description and Business Overview
        6.23.3 Mylan Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.23.4 Mylan Aflibercept Biosimilars Product Portfolio
        6.23.5 Mylan Recent Developments/Updates
    6.24 BeiGene
        6.24.1 BeiGene Corporation Information
        6.24.2 BeiGene Aflibercept Biosimilars Description and Business Overview
        6.24.3 BeiGene Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.24.4 BeiGene Aflibercept Biosimilars Product Portfolio
        6.24.5 BeiGene Recent Developments/Updates
    6.25 Innovent
        6.25.1 Innovent Corporation Information
        6.25.2 Innovent Aflibercept Biosimilars Description and Business Overview
        6.25.3 Innovent Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.25.4 Innovent Aflibercept Biosimilars Product Portfolio
        6.25.5 Innovent Recent Developments/Updates
    6.26 Qilu Pharmaceutical
        6.26.1 Qilu Pharmaceutical Corporation Information
        6.26.2 Qilu Pharmaceutical Aflibercept Biosimilars Description and Business Overview
        6.26.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.26.4 Qilu Pharmaceutical Aflibercept Biosimilars Product Portfolio
        6.26.5 Qilu Pharmaceutical Recent Developments/Updates
    6.27 Hengrui Pharmaceuticals
        6.27.1 Hengrui Pharmaceuticals Corporation Information
        6.27.2 Hengrui Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
        6.27.3 Hengrui Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.27.4 Hengrui Pharmaceuticals Aflibercept Biosimilars Product Portfolio
        6.27.5 Hengrui Pharmaceuticals Recent Developments/Updates
    6.28 Hisun Pharmaceutical
        6.28.1 Hisun Pharmaceutical Corporation Information
        6.28.2 Hisun Pharmaceutical Aflibercept Biosimilars Description and Business Overview
        6.28.3 Hisun Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.28.4 Hisun Pharmaceutical Aflibercept Biosimilars Product Portfolio
        6.28.5 Hisun Pharmaceutical Recent Developments/Updates
    6.29 TOT BIOPHARM
        6.29.1 TOT BIOPHARM Corporation Information
        6.29.2 TOT BIOPHARM Aflibercept Biosimilars Description and Business Overview
        6.29.3 TOT BIOPHARM Aflibercept Biosimilars Sales, Revenue and Gross Margin (2017-2022)
        6.29.4 TOT BIOPHARM Aflibercept Biosimilars Product Portfolio
        6.29.5 TOT BIOPHARM Recent Developments/Updates
7 Aflibercept Biosimilars Manufacturing Cost Analysis
    7.1 Aflibercept Biosimilars Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Aflibercept Biosimilars
    7.4 Aflibercept Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Aflibercept Biosimilars Distributors List
    8.3 Aflibercept Biosimilars Customers
9 Aflibercept Biosimilars Market Dynamics
    9.1 Aflibercept Biosimilars Industry Trends
    9.2 Aflibercept Biosimilars Market Drivers
    9.3 Aflibercept Biosimilars Market Challenges
    9.4 Aflibercept Biosimilars Market Restraints
10 Global Market Forecast
    10.1 Aflibercept Biosimilars Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Aflibercept Biosimilars by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Aflibercept Biosimilars by Type (2023-2028)
    10.2 Aflibercept Biosimilars Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Aflibercept Biosimilars by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Aflibercept Biosimilars by Application (2023-2028)
    10.3 Aflibercept Biosimilars Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Aflibercept Biosimilars by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Aflibercept Biosimilars by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer
List of Tables
    Table 1. Global Aflibercept Biosimilars Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
    Table 2. Global Aflibercept Biosimilars Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
    Table 3. Global Aflibercept Biosimilars Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Aflibercept Biosimilars Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Aflibercept Biosimilars Sales (K Units) of Key Manufacturers (2017-2022)
    Table 6. Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Aflibercept Biosimilars Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Aflibercept Biosimilars Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Aflibercept Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Aflibercept Biosimilars Manufacturing Sites and Area Served
    Table 11. Manufacturers Aflibercept Biosimilars Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Aflibercept Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Aflibercept Biosimilars as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Aflibercept Biosimilars Sales by Region (2017-2022) & (K Units)
    Table 16. Global Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
    Table 17. Global Aflibercept Biosimilars Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
    Table 19. North America Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
    Table 20. North America Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
    Table 21. North America Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
    Table 23. Europe Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
    Table 24. Europe Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
    Table 25. Europe Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Aflibercept Biosimilars Sales by Region (2017-2022) & (K Units)
    Table 28. Asia Pacific Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Aflibercept Biosimilars Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
    Table 32. Latin America Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
    Table 33. Latin America Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
    Table 36. Middle East and Africa Aflibercept Biosimilars Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Aflibercept Biosimilars Revenue Market Share by Country (2017-2022)
    Table 39. Global Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
    Table 40. Global Aflibercept Biosimilars Sales Market Share by Type (2017-2022)
    Table 41. Global Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Aflibercept Biosimilars Revenue Share by Type (2017-2022)
    Table 43. Global Aflibercept Biosimilars Price by Type (2017-2022) & (K USD/Unit)
    Table 44. Global Aflibercept Biosimilars Sales (K Units) by Application (2017-2022)
    Table 45. Global Aflibercept Biosimilars Sales Market Share by Application (2017-2022)
    Table 46. Global Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Aflibercept Biosimilars Revenue Share by Application (2017-2022)
    Table 48. Global Aflibercept Biosimilars Price by Application (2017-2022) & (K USD/Unit)
    Table 49. Regeneron Corporation Information
    Table 50. Regeneron Description and Business Overview
    Table 51. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 52. Regeneron Aflibercept Biosimilars Product
    Table 53. Regeneron Recent Developments/Updates
    Table 54. Sanofi Corporation Information
    Table 55. Sanofi Description and Business Overview
    Table 56. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 57. Sanofi Aflibercept Biosimilars Product
    Table 58. Sanofi Recent Developments/Updates
    Table 59. Novartis Corporation Information
    Table 60. Novartis Description and Business Overview
    Table 61. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 62. Novartis Aflibercept Biosimilars Product
    Table 63. Novartis Recent Developments/Updates
    Table 64. Genentech Corporation Information
    Table 65. Genentech Description and Business Overview
    Table 66. Genentech Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 67. Genentech Aflibercept Biosimilars Product
    Table 68. Genentech Recent Developments/Updates
    Table 69. Roche Corporation Information
    Table 70. Roche Description and Business Overview
    Table 71. Roche Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 72. Roche Aflibercept Biosimilars Product
    Table 73. Roche Recent Developments/Updates
    Table 74. Pfizer Corporation Information
    Table 75. Pfizer Description and Business Overview
    Table 76. Pfizer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 77. Pfizer Aflibercept Biosimilars Product
    Table 78. Pfizer Recent Developments/Updates
    Table 79. Sartorius Corporation Information
    Table 80. Sartorius Description and Business Overview
    Table 81. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 82. Sartorius Aflibercept Biosimilars Product
    Table 83. Sartorius Recent Developments/Updates
    Table 84. Eli Lilly Corporation Information
    Table 85. Eli Lilly Description and Business Overview
    Table 86. Eli Lilly Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 87. Eli Lilly Aflibercept Biosimilars Product
    Table 88. Eli Lilly Recent Developments/Updates
    Table 89. Bayer Corporation Information
    Table 90. Bayer Description and Business Overview
    Table 91. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 92. Bayer Aflibercept Biosimilars Product
    Table 93. Bayer Recent Developments/Updates
    Table 94. Amgen Corporation Information
    Table 95. Amgen Description and Business Overview
    Table 96. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 97. Amgen Aflibercept Biosimilars Product
    Table 98. Amgen Recent Developments/Updates
    Table 99. PlantForm Corporation Information
    Table 100. PlantForm Description and Business Overview
    Table 101. PlantForm Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 102. PlantForm Aflibercept Biosimilars Product
    Table 103. PlantForm Recent Developments/Updates
    Table 104. PharmaPraxis Corporation Information
    Table 105. PharmaPraxis Description and Business Overview
    Table 106. PharmaPraxis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 107. PharmaPraxis Aflibercept Biosimilars Product
    Table 108. PharmaPraxis Recent Developments/Updates
    Table 109. Samsung Bioepis Corporation Information
    Table 110. Samsung Bioepis Description and Business Overview
    Table 111. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 112. Samsung Bioepis Aflibercept Biosimilars Product
    Table 113. Samsung Bioepis Recent Developments/Updates
    Table 114. Centus Corporation Information
    Table 115. Centus Description and Business Overview
    Table 116. Centus Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 117. Centus Aflibercept Biosimilars Product
    Table 118. Centus Recent Developments/Updates
    Table 119. Cadila Pharmaceuticals Corporation Information
    Table 120. Cadila Pharmaceuticals Description and Business Overview
    Table 121. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 122. Cadila Pharmaceuticals Aflibercept Biosimilars Product
    Table 123. Cadila Pharmaceuticals Recent Developments/Updates
    Table 124. Dr Reddy's Corporation Information
    Table 125. Dr Reddy's Description and Business Overview
    Table 126. Dr Reddy's Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 127. Dr Reddy's Aflibercept Biosimilars Product
    Table 128. Dr Reddy's Recent Developments/Updates
    Table 129. Aurobindo Pharma Corporation Information
    Table 130. Aurobindo Pharma Description and Business Overview
    Table 131. Aurobindo Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 132. Aurobindo Pharma Aflibercept Biosimilars Product
    Table 133. Aurobindo Pharma Recent Developments/Updates
    Table 134. Biocad Corporation Information
    Table 135. Biocad Description and Business Overview
    Table 136. Biocad Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 137. Biocad Aflibercept Biosimilars Product
    Table 138. Biocad Recent Developments/Updates
    Table 139. MAbxience Corporation Information
    Table 140. MAbxience Description and Business Overview
    Table 141. MAbxience Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 142. MAbxience Aflibercept Biosimilars Product
    Table 143. MAbxience Recent Developments/Updates
    Table 144. Hetero Corporation Information
    Table 145. Hetero Description and Business Overview
    Table 146. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 147. Hetero Aflibercept Biosimilars Product
    Table 148. Hetero Recent Developments/Updates
    Table 149. Biocon Corporation Information
    Table 150. Biocon Description and Business Overview
    Table 151. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 152. Biocon Aflibercept Biosimilars Product
    Table 153. Biocon Recent Developments/Updates
    Table 154. Kirin Biologics Corporation Information
    Table 155. Kirin Biologics Description and Business Overview
    Table 156. Kirin Biologics Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 157. Kirin Biologics Aflibercept Biosimilars Product
    Table 158. Kirin Biologics Recent Developments/Updates
    Table 159. Mylan Corporation Information
    Table 160. Mylan Description and Business Overview
    Table 161. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 162. Mylan Aflibercept Biosimilars Product
    Table 163. Mylan Recent Developments/Updates
    Table 164. BeiGene Corporation Information
    Table 165. BeiGene Description and Business Overview
    Table 166. BeiGene Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 167. BeiGene Aflibercept Biosimilars Product
    Table 168. BeiGene Recent Developments/Updates
    Table 169. Innovent Corporation Information
    Table 170. Innovent Description and Business Overview
    Table 171. Innovent Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 172. Innovent Aflibercept Biosimilars Product
    Table 173. Innovent Recent Developments/Updates
    Table 174. Qilu Pharmaceutical Corporation Information
    Table 175. Qilu Pharmaceutical Description and Business Overview
    Table 176. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 177. Qilu Pharmaceutical Aflibercept Biosimilars Product
    Table 178. Qilu Pharmaceutical Recent Developments/Updates
    Table 179. Hengrui Pharmaceuticals Corporation Information
    Table 180. Hengrui Pharmaceuticals Description and Business Overview
    Table 181. Hengrui Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 182. Hengrui Pharmaceuticals Aflibercept Biosimilars Product
    Table 183. Hengrui Pharmaceuticals Recent Developments/Updates
    Table 184. Hisun Pharmaceutical Corporation Information
    Table 185. Hisun Pharmaceutical Description and Business Overview
    Table 186. Hisun Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 187. Hisun Pharmaceutical Aflibercept Biosimilars Product
    Table 188. Hisun Pharmaceutical Recent Developments/Updates
    Table 189. TOT BIOPHARM Corporation Information
    Table 190. TOT BIOPHARM Description and Business Overview
    Table 191. TOT BIOPHARM Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
    Table 192. TOT BIOPHARM Aflibercept Biosimilars Product
    Table 193. TOT BIOPHARM Recent Developments/Updates
    Table 194. Production Base and Market Concentration Rate of Raw Material
    Table 195. Key Suppliers of Raw Materials
    Table 196. Aflibercept Biosimilars Distributors List
    Table 197. Aflibercept Biosimilars Customers List
    Table 198. Aflibercept Biosimilars Market Trends
    Table 199. Aflibercept Biosimilars Market Drivers
    Table 200. Aflibercept Biosimilars Market Challenges
    Table 201. Aflibercept Biosimilars Market Restraints
    Table 202. Global Aflibercept Biosimilars Sales Forecast by Type (2023-2028) & (K Units)
    Table 203. Global Aflibercept Biosimilars Sales Market Share Forecast by Type (2023-2028)
    Table 204. Global Aflibercept Biosimilars Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 205. Global Aflibercept Biosimilars Revenue Market Share Forecast by Type (2023-2028)
    Table 206. Global Aflibercept Biosimilars Sales Forecast by Application (2023-2028) & (K Units)
    Table 207. Global Aflibercept Biosimilars Sales Market Share Forecast by Application (2023-2028)
    Table 208. Global Aflibercept Biosimilars Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 209. Global Aflibercept Biosimilars Revenue Market Share Forecast by Application (2023-2028)
    Table 210. Global Aflibercept Biosimilars Sales Forecast by Region (2023-2028) & (K Units)
    Table 211. Global Aflibercept Biosimilars Sales Market Share Forecast by Region (2023-2028)
    Table 212. Global Aflibercept Biosimilars Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 213. Global Aflibercept Biosimilars Revenue Market Share Forecast by Region (2023-2028)
    Table 214. Research Programs/Design for This Report
    Table 215. Key Data Information from Secondary Sources
    Table 216. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Aflibercept Biosimilars
    Figure 2. Global Aflibercept Biosimilars Market Share by Type in 2021 & 2028
    Figure 3. Intravitreal Injection Product Picture
    Figure 4. Intravenous Injection Product Picture
    Figure 5. Global Aflibercept Biosimilars Market Share by Application in 2021 & 2028
    Figure 6. Wet Macular Degeneration
    Figure 7. Metastatic Colorectal Cancer
    Figure 8. Global Aflibercept Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 9. Global Aflibercept Biosimilars Market Size (2017-2028) & (US$ Million)
    Figure 10. Global Aflibercept Biosimilars Sales (2017-2028) & (K Units)
    Figure 11. Aflibercept Biosimilars Sales Share by Manufacturers in 2021
    Figure 12. Global Aflibercept Biosimilars Revenue Share by Manufacturers in 2021
    Figure 13. The Global 5 and 10 Largest Aflibercept Biosimilars Players: Market Share by Revenue in 2021
    Figure 14. Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 15. Global Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
    Figure 16. Global Aflibercept Biosimilars Sales Market Share by Region in 2021
    Figure 17. Global Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
    Figure 18. Global Aflibercept Biosimilars Revenue Market Share by Region in 2021
    Figure 19. United States Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 20. Canada Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 21. Germany Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 22. France Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. U.K. Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Italy Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. Russia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. China Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Japan Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. South Korea Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. India Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. Australia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. China Taiwan Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. Indonesia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Thailand Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. Malaysia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Mexico Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Brazil Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Argentina Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Turkey Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Saudi Arabia Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. UAE Aflibercept Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Sales Market Share of Aflibercept Biosimilars by Type (2017-2022)
    Figure 42. Manufacturing Cost Structure of Aflibercept Biosimilars
    Figure 43. Manufacturing Process Analysis of Aflibercept Biosimilars
    Figure 44. Aflibercept Biosimilars Industrial Chain Analysis
    Figure 45. Channels of Distribution
    Figure 46. Distributors Profiles
    Figure 47. Bottom-up and Top-down Approaches for This Report
    Figure 48. Data Triangulation
    Figure 49. Key Executives Interviewed